Of course better for professional cha cha dancers. 4 rounds of successful GenB trades this year.
Posted here last night that LKT selling his GenB shares in large volumes daily. Smart traders would have cleared their balance this morning. The dumb fake investor whose average prices can auto drop from 4.50, 4.20, 4.00, 3.50, etc can even give delusional talk abt M&A of GenB at high price.
"Staying Alive", "Staurday Night Fever"... those are baby boomers era of music and movies. Kekeke....
BTW I swear to God and Hell that I am still below fifty years old. Usually teenager or below will call me uncle, thats fine. I never hear before baby boomers calling me uncle. Real become fake, young become old.... Fake become real, old become young..... Only thru the delusional lens and foul mouth of a cha cha aunty. Hahaha.
*Technical tracker - HLIB Retail Research – 9 June 2022*
*GENTING: Another leg up?*
*TauRx, the next crown jewel? Following TauRx’s (20.3% owned by GENTING) announcement on 31 May that it is moving ahead for regulatory submission on its Alzheimer’s treatment, the group will follow up with an update at the 35th Global Conference of Alzheimer’s disease today. In our view, any positive finding is likely to create another up-leg in GENTING share prices due to potential value unlocking in TauRx.*
*To recap, TauRx aimed to be listed with a valuation of USD15bn back in 2016. However, the plan was put on hold as it failed in late clinical trial for its Alzheimer’s treatment. By taking the same valuation of USD15bn (if the drug is commercialized), this will translate to an effective stake of USD3.05bn, which is 64% of GENTING’s market cap based on the 8 June closing price. As the market has yet to bake in TauRx into GENTING’s valuation, any upward revision of its TP following the commercialisation of TauRx’s drug should bode well for share prices.*
*Better days ahead. Apart from the potential re-rating catalyst in TauRx, GENTING’s gaming business is set to recover and potentially turnaround in the subsequent quarters, after losing for 5 straight quarters. This is premised on (i) capacity increase in hotel operations; (ii) contribution from SkyWorlds; and (iii) the weak RM currency, which augurs well for both local tourism and foreign visitations. We continue to like GENTING due to its deep expertise and experience in managing the gaming and hospitality businesses and its well-spread operations across different regions, which helps to mitigate regulatory and country risks. All in, HLIB reiterates a BUY call with a target price of RM6.50, translating into a 21.7% upside from the current level. Downside risk is limited as the stock is currently trading at 8.47x FY23 EV/EBITDA (23% discount vs 5Y average mean of 11x).* *Long-term resistance breakout. Technically, GENTING had performed a long-term resistance (RM5.27) breakout yesterday
After dumping, (ockTah! still has 18.64 mil shrs more than what he was holding in Dec '18, before increasing further in Dec '19 & Jan '20 just b4 corona crashed the shares.
When red happens, han tu Aunty Atk appears sampat talk… Hahaha. Thanks for sharing latest news @ETTUSA --------------------------------------------------
As usual, cha cha aunty always jealous of ATK. See the profile picture? Its a man lah... man become woman... cha cha aunty has both dementia and serious eyesight problems? LoseSSP is also an oldman like Amboi oldman? No wonder birds of same feathers flock together. Kekeke....
If you are joining us today, either online or in-person for #ADI2022, follow our Twitter channel for live updates from the conference. Throughout the next 3 days, we will be sharing highlights from the conference programme, as well insights and commentary from delegates. Bookmark or follow us on Twitter: https://twitter.com/alzdisint?fbclid=IwAR1dnc54exAg8AK5y4LRhkW3e5Mz2i8scyqCZ1YPSZsykMivIDOi2aatbv4
12-months safety and efficacy data of the Phase 3 LUCIDITY trial, a randomized, double-blind, placebo-controlled, 12-month, safety, and efficacy study of hydromethylthionine mesylate (HMTM) 16 mg/day oral tablet monotherapy in patients with MCI due to probable AD or mild-moderate AD.
LUCIDITY will continue to run for a further 12 months open label phase during which all study patients have access to the 16mg/day oral dose, with expected end results May 2023.
This session will share available information and includes an independent panel discussion on the potential impact of the trial outcome for people with dementia across the spectrum of mild cognitive impairment (MCI) to moderate Alzheimer’s disease, and the future direction of AD research.
Aunty Atk Dementia yapping non-stop. Pergi tidur la lol ---------------------------------------------
Dementia cha cha old aunty LoseSSP keep posting and deleting her previous posts. You were yapping non-stop the entire day. I only came in later. You forgot already? Cha cha old aunty's posts also has dementia, miraculously deleted, disappeared and forgotten too.
No time to poke back at fake investor old aunty liow. Watching out for my real investment Taurx's result. Cha cha cha... Jeng Jeng Jeng....
On serious note, i wish Taurx all the best on their final trial! Alzheimer is a serious disease! So far no medication has been found! This would be the first on the market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Income
13,071 posts
Posted by Income > 2022-06-09 14:58 | Report Abuse
Do you know that Turkey’s name already approved by UN for a new name…
You can Google Turkey new name. I forgot how to spell Turkey new name.
So foolish Turkey … changed name to a new name, I also can’t pronounce it and can’t spell its new name.